Resources Repository
-
ReportPublication 2015Modeling to Improve Policy Decisions in the Americas: Noncommunicable Diseases
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only …
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only to human health, but also to a country’s economic development and growth. The evidence on both of these counts is compelling. In 2012, cardiovascular disease, diabetes, cancers, chronic respiratory conditions including asthma, and other NCDs were the cause of 4.5 million deaths in the Americas. Of that total number, 1.5 million of them were premature, occurring among people aged 30-69…
Priority Setting/Ethics | Microsimulation | Decision Analysis | Health/Medicine | Costing Methods | Mathematical Models | State-Transition | Cost-Effectiveness Analysis | Chronic Disease/Risk | Mental Health | Latin America & Caribbean -
ArticlePublication 2021Health Opportunity Cost Threshold for CEA in the U.S.
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, …
Using a modeled cohort of 100,000 individuals in the United States with private health insurance, the authors simulated the short-term mortality and morbidity resulting from increased premium related cancelation of insurance coverage. The authors used this model to estimate cost-effectiveness thresholds, in dollars per quality-adjusted life year (QALY) gained based on health opportunity costs. They reported the number of persons who dropped insurance coverage, resulting number of additional deaths and QALYs lost from mortality and…
Priority Setting/Ethics | Microsimulation | Health/Medicine | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | North America -
ToolInteractive, Teaching Resource 2020RAND Critical Care Surge Response Tool
This Excel-based model allows decisionmakers at all levels (i.e., hospitals, health care systems, states, regions) …
This Excel-based model allows decisionmakers at all levels (i.e., hospitals, health care systems, states, regions) to examine the current critical care capacity in the nation’s hospitals and rapidly explore strategies for increasing capacity to provide care for the sickest COVID-19 patients. The tool was developed by the RAND Corporation in response to the 2020 COVID-19 pandemic. Model input parameters to the Excel spreadsheet include baseline number of beds, critical care doctors and nurses, respiratory therapists,…
Priority Setting/Ethics | Operations Research | Health/Medicine | Mathematical Models | Infectious Diseases | North America | Professional | Policy Translation -
ArticlePublication 2016Health and Economic Benefits of Public Financing of Epilepsy Treatment in India
This study uses extended cost-effectiveness analysis (ECEA) to evaluate the impact of three scenarios of …
This study uses extended cost-effectiveness analysis (ECEA) to evaluate the impact of three scenarios of publicly financed national epilepsy programs in India that provide (1) first line antiepilepsy drugs (AEDs), (2) first- and second-line AEDs, and (3) first- and second-line AEDs and surgery. Outcome measures include disability-adjusted life years (DALYs) averted, and cost per DALY averted. Economic benefit measures estimated include out-of-pocket (OOP) expenditure averted and money-metric value of insurance. All three scenarios represent a…
Priority Setting/Ethics | Microsimulation | Health/Medicine | Cost-Effectiveness Analysis | Chronic Disease/Risk | Economics/Finance | Asia & Pacific -
Resource PackPublication, Teaching Resource 2019Resource Pack: BCA in Low- and Middle-Income Countries
This resource pack, curated by the Center for Health Decision Science, includes methods papers, case …
This resource pack, curated by the Center for Health Decision Science, includes methods papers, case studies, and reference case guidance for conducting benefit-cost analyses in low- and middle-income countries. These resources will aid advanced students and experienced practitioners in preparing these analyses. Investing in global health and development requires making difficult choices about what initiatives to fund and what level of resources to devote to each initiative. Although benefit-cost analysis is a well-established and widely-used…
Priority Setting/Ethics | Decision Analysis | Health/Medicine | Preferences/Values | Benefit-Cost Analysis | Social Determinants | Policy/Regulation | Economics/Finance | Global | Graduate | Doctoral | Professional | Critical Thinking/Analysis -
Resource PackPublication, Teaching Resource 2024Resource Pack: Introduction to Benefit-Cost Analysis
This resource pack, curated by the Center for Health Decision Science, introduces the theory and …
This resource pack, curated by the Center for Health Decision Science, introduces the theory and practice of benefit-cost analysis. It is targeted towards advanced students as well as practitioners and those interested in teaching benefit-cost analysis. Benefit-cost analysis (also referred to as cost-benefit analysis) is a well-established and widely-used form of economic evaluation. It is designed to inform policy and other decisions by providing evidence on the consequences of alternative interventions. In benefit-cost analysis, all…
Priority Setting/Ethics | Decision Analysis | Health/Medicine | Preferences/Values | Benefit-Cost Analysis | Social Determinants | Policy/Regulation | Climate/Environment | Economics/Finance | Government/Law | Global | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis -
ArticlePublication 2018Should We Treat Acute Hepatitis C? A Decision and Cost-Effectiveness Analysis
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared …
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared to deferring treatment until the chronic phase, utilizing a microsimulation model. By projecting long-term outcomes such as quality-adjusted life years (QALYs) and costs, the analysis evaluates the cost-effectiveness of initiating therapy during the acute phase. Results indicate that treating acute HCV increases QALYs by 0.02 and costs by $483 per patient not at risk of transmitting HCV, yielding an incremental…
Microsimulation | Decision Analysis | Health/Medicine | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | North America -
Working PaperPublication 2018Valuing Nonfatal Health Risk Reductions
This paper explores approaches for valuing nonfatal risk reductions associated with policy choices in low- …
This paper explores approaches for valuing nonfatal risk reductions associated with policy choices in low- and middle-income countries. The approach for valuation ideally would be based on estimates of individuals’ willingness to pay for changes in their own risks. However, high quality valuation research is not available for many nonfatal conditions even in high-income settings. Typically, two approaches are used either alone or in combination as rough proxies. The first involves applying an estimate of…
Priority Setting/Ethics | Decision Analysis | Health/Medicine | Preferences/Values | Health Outcomes | Benefit-Cost Analysis | Social Determinants | Policy/Regulation | Economics/Finance | Global | Critical Thinking/Analysis -
ArticleWeb Portal 2017PLOS Collection: Economic Efficiency of HIV Services
In order to maximize the value for money for HIV services and increase efficiency without …
In order to maximize the value for money for HIV services and increase efficiency without sacrificing quality, robust and up-to-date data on costs, efficiency and its determinants are needed. This PLOS collection, Economic Efficiency of HIV Services, presents recent, high-quality evidence from low- and middle-income countries on costs and technical efficiency of HIV services and their determinants. These data contribute to the current discussion on optimizing resources for HIV services and can provide programmatic guidance for…
Priority Setting/Ethics | Operations Research | Health/Medicine | Costing Methods | Cost-Effectiveness Analysis | Infectious Diseases | Economics/Finance | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific